Literature DB >> 1110869

Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride).

H J Dietzsch, B Gottschalk, K Heyne, W Leupoid, P Wunderlich.   

Abstract

Clinical, bronchoscopic, spirographic, scintigraphic, and chemical analyses were done in 24 children with cystic fibrosis to assess the mucolytic effects of acetylcysteine inhalations versus L-arginine hydrochloride aerosols. The latter drug is less active than acetylcysteine and should not be used to treat children with cystic fibrosis.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1110869

Source DB:  PubMed          Journal:  Pediatrics        ISSN： 0031-4005            Impact factor:   7.124


  10 in total

1.  Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms.

Authors:  Giorgia Borriello; Lee Richards; Garth D Ehrlich; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Aztreonam lysine for inhalation solution in cystic fibrosis: profile report.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

3.  An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Authors:  Christopher M Oermann; George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Pediatr Pulmonol       Date:  2010-11

Review 4.  Aztreonam lysine for inhalation solution: in cystic fibrosis.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

Review 5.  Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.

Authors:  Julian Tam; Edward F Nash; Felix Ratjen; Elizabeth Tullis; Anne Stephenson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-12

6.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Authors:  George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Christopher M Oermann; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

7.  Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Karen S McCoy; Alexandra L Quittner; Christopher M Oermann; Ronald L Gibson; George Z Retsch-Bogart; A Bruce Montgomery
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

8.  Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis.

Authors:  Martha K Daddario; Jennifer K Hagerman; Michael E Klepser
Journal:  Infect Drug Resist       Date:  2010-10-28       Impact factor: 4.003

9.  Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.

Authors:  Stephen Kirkby; Kimberly Novak; Karen McCoy
Journal:  Core Evid       Date:  2011-08-11

10.  An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.

Authors:  Camille Ehre; Zachary L Rushton; Boya Wang; Lauren N Hothem; Cameron B Morrison; Nicholas C Fontana; Matthew R Markovetz; Martial F Delion; Takafumi Kato; Diane Villalon; William R Thelin; Charles R Esther; David B Hill; Barbara R Grubb; Alessandra Livraghi-Butrico; Scott H Donaldson; Richard C Boucher
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 30.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.